Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Active Biotech on rights offering (3)
Mandate

Vinge advises Active Biotech on rights offering

August 05, 2022

Active Biotech AB (publ) (Nasdaq Stockholm) carries out a rights issue of approximately SEK 55 million.

Vinge advises Active Biotech. Vinge’s team primarily consists of Christian Lindhé, Erik Sjöman, Astrid Isberg and Johanne Örnfeldt Svensson.

Related

Vinge has advised Eleda in connection with Eleda Norge AS’s acquisition of Nettpartner Bane AS

 Vinge, together with Advokatfirmaet Thommessen, has advised Eleda in connection with Eleda Norge AS’s acquisition of Nettpartner Bane AS from Å Energi owned Nettpartner AS.
January 19, 2026

Vinge advises KEYTO Group in connection with the acquisition of Smartify

 KEYTO Group continues its growth journey by strengthening its offering in Sweden as Smartify Sverige AB joins KEYTO Group.
January 19, 2026

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

 Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026